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ABSTRACT
The use of plasmid DNA (pDNA) for human vaccines is a novel approach against leishmaniasis,
a neglected tropical disease with severe clinical manifestations. The development of feasible
bioprocesses to obtain such vaccines is a public-health priority. The aim of this work was to
investigate the substrate-source flexibility of an exponential-fed perfusion (EFP) system to
produce the plasmid pVAX1-NH36 for use as a leishmaniasis vaccine. Batch and EFP cultures
were conducted using Escherichia coli DH5a as a host and glucose or glycerol as a carbon
source. The culture kinetics of the cell, substrate and plasmid concentrations were measured.
Mathematical kinetics models were fitted to experimental data and used to describe the system
comportment (r2> 0.95). Plasmid productivities of 13.3mg/(L h) using glucose and 19.4mg/(L h)
using glycerol were obtained. These levels represent a 1–3-fold increase in performance index
compared with previously reported cultures using E. coli DH5a. The novel aspect of this work is
the demonstration of the flexibility of EFP cultures for production of pDNA vaccines. Our data
suggest that E. coli engineering to increase pDNA production using glucose can be circum-
vented with an EFP culture, reducing the host strain development costs. In addition, the greater
productivity of EFP cultures entails a reduction in manufacturing costs.
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Introduction
The employment of plasmid DNA (pDNA) vaccines is a
new technology to mimic infections and generate a
resilient immune response [1]. The advances made in
pDNA design, delivery, formulation and manufacturing
have been reviewed recently [2,3]. pDNA vaccines are
candidates for several diseases [4], but have only been
licensed for veterinary use [5]. However, several clinical
studies of human pDNA vaccines are currently being
developed against challenging diseases and viral
pandemics [6,7]. Hence, the DNA vaccination market is
growing and demands the development of sustainable
industrial bioprocesses to produce pDNA [8–10].
Leishmaniasis is prevalent mainly in countries with
limited resources, where it presents millions of human
infections each year [11]. It is categorized as a
neglected tropical disease (NTD) and occupies first
place in the disability-adjusted life years (DALYs) rank,
representing years of life lost for premature death plus
years lived with disability [12]. Leishmaniasis comprises
a group of diseases caused by obligate intracellular
parasites, belonging to the genus Leishmania,
which infect mononuclear phagocytes [13]. Their
pathogenicity ranges from mild cutaneous lesions to
severe organ injuries. The transmission of leishmaniasis
occurs by the bite of a sand fly belonging to the
genus Phlebotomus and Lutzomiya [14].
The development of a vaccine is currently
perceived as the right approach to battle leishmaniasis
and is considered a social priority [15]. In particular, a
pDNA vaccine carrying the nucleoside hydrolase NH36
gene is a suitable candidate for this purpose [16,17].
First-generation vaccines are typically produced using
eukaryotic cells, while pDNA is manufactured using a bac-
terial host in high cell density cultures (HCDC), resulting in
improved production systems [18]. Plasmid solutions
obtained in Escherichia coli cultures contain supercoiled
(CCC), open circular (OC) and linear (L) isoforms [19].
Isoform CCC pDNA is recommended by regulatory
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agencies for vaccine treatments due to the structural
alterations present in the OC and L isoforms [20].
The key performance parameters of pDNA produc-
tion bioprocesses, besides vector design and host
strain, depend on culture medium design, growth
conditions, and purification strategy [21–23]. Several
cultivation reports have shown an inverse relationship
between plasmid content and growth rate, and control
of this kinetic parameter at low values during the
culture has been recommended, but more research is
required to better understand this behaviour [8].
An improper cultivation environment can reduce
the percentage of pDNA yield. For example, it has
been observed that the changes associated with
the transition at the end of the conventional culture
modes appear to increase the genomic contamination
[24]. The use of synthetic growth medium for pDNA
production is recommended by regulatory guidelines
[2]. An important consideration is the medium com-
position including the carbon source, since it can
affect this production [25]. It has been reported that
E. coli DH5a produces more pDNA in HCDC using gly-
cerol than using glucose. Moreover, the use of glucose
increases the surplus acetate production [10,26].
A fundamental decision in the process development
is the selection between batch, fed-batch and perfu-
sion bioreactors (Figure 1) [4,23,25]. The operating time
of HCDC in batch and fed-batch modes for pDNA pro-
duction is restricted by the concentration of unwanted
substances and plasmid instability [27]. The perfusion
mode can circumvent these restrictions, since the
exhausted medium is eliminated and the growth rate is
controlled with the substrate feed-rate, resulting in less
cell injury, and higher CCC pDNA yield and productivity
compared with fed-batch cultures [4,23].
The technical feasibility of EFP culture has been
demonstrated using the conventional approach of
glycerol-limited culture [28]. The competitive prices of
glycerol support this practice [29], but the develop-
ment of flexible processes suitable to metabolise
glucose or glycerol as substrate is pertinent for indus-
trial plasmid manufacturing [23]. Nevertheless, it is
necessary to consider that plasmid yield and purity are
affected by the type of nutrients or by oxygen
limitation [30], and the flexibility-based relevance of
EFP cultures needs to be demonstrated experimentally.
In this study, the flexibility of an EFP culture to
produce pVAX1-NH36 was investigated using glucose or
glycerol as carbon source. A model of cell, substrate
and plasmid kinetics was solved numerically, fitted to
the data and used to analyze the system’s comportment
and flexibility. In addition, the oxygen demand and
control with each carbon source were also evaluated.
Materials and methods
Host strain and plasmid
The E. coli DH5a strain hosting pVAX1-NH36 (4.0 kbp)
used in this work was acquired form CINVESTAV-IPN
(Mexico City, Mexico) [31].
Culture conditions
Three batch cultures were performed using a defined
medium with each substrate (glucose or glycerol) and
the same experimental conditions in order to obtain
the culture kinetics parameters. The information
obtained was used to experimentally reproduce EFP
cultures with each carbon source.
Figure 1. Modes of operation of bioreactors for pDNA production and medium colour comparison.
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Culture medium
A mineral salt medium was employed with glucose or
glycerol as carbon source as described previously [10].
The batch cultures and the initial batch phase of
the EFP cultures started with 13.0 g/L of the carbon
substrate. In the EFP phase, a defined medium
solution with 18 g/L of the carbon source was fed to
the bioreactor.
Bioreactor cultivations
To implement the batch and perfusion cultures, a 3.0 L
stirred-tank bioreactor (ApplikonVR Biotechnology, Delft,
The Netherlands) with an operational volume of 1.0 L
was used as described in a prior study [4], except that
pH was controlled at 6.7 ± 0.05 using a 28% NH4OH
solution. Dissolved oxygen (DO) was controlled at 30%
of saturation combining agitation, aeration and pure
oxygen pulses.
Additionally, we used the KrosFlo Research III
tangential flow filtration (TFF) system with a UF unit
X3-500S-300-02N (SpectrumVR Laboratories, Inc., Rancho
Dominguez, CA, USA) for EFP cultures. Fermentations
started in a batch mode to increase cell mass. When
the substrate was exhausted, an exponential feed was
applied to keep a perfusion growth rate of mp¼ 0.25h1.
Analytical methods
Biomass and substrate determination
The optical density at 600 nm (OD600) of the culture
samples taken was measured in a UV-1600PC
spectrometer (VRWVR , United States). Glucose was
determined with a kit glucose (GO) assay and glycerol
using free glycerol reagent (Sigma-Aldrich, USA).
Plasmid analysis
For determining plasmid content, samples with
uniform cell mass were obtained during the culture.
Each sample was lysed and then centrifuged,
obtaining a pellet for plasmid preparation. We used
HIC-HPLC analysis to measure pDNA concentration, as
reported in the literature [32]. Plasmid solutions
were also examined by electrophoresis as described
previously [4], except that they were run on agarose
gel (0.8%) at 60 V for 120min.
Mathematical model
The corresponding kinetic model for the EFP process
has been reported recently [28]. In this work, the
model was validated and used to reproduce the EFP
cultures and to analyze the system’s performance. The
simulation studies were conducted using MATLAB.
Results and discussion
Batch cultures
Cell growth and substrate consumption
Figure 2(a,b) shows the biomass growth and substrate
consumption kinetics of the batch cultures. The
culture using glucose lasted for 5.5 h and a maximum
cell density of 16.36 OD600 was obtained (Figure 2a).
The culture using glycerol lasted for 5.0 h and a
maximum cell density of 12.50 OD600 was obtained
(Figure 2b). The simulation results of the three batch
cultures presented an adequate adjustment to the
kinetic data with r2 0.98 for both biomass and
substrate concentration. The corresponding operating
and kinetic parameters are shown in Table 1.
Plasmid kinetics and yield
The plasmid kinetics in batch cultures using glucose
or glycerol are shown in Figure 2(c,d). In the glucose
batch experiment (Figure 2c), the final plasmid specific
yield (SY) was 1.35mg/(LOD600) and the volumetric
yield (VY) was 22.10mg/L. Plasmid specific yield
decreased as the cell growth rate increased due to a
dilution effect, which is one of the limitations of
batch cultures for plasmid production. However, the
volumetric yield increased due to the quantitative
effect of cell growth.
In the glycerol batch experiments (Figure 2(d)), the
final plasmid SY was 2.70mg/(LOD600) and the VY was
33.75mg/L. Plasmid specific yield increased during the
culture due to a lower specific growth rate. In all
the batch experiments, the models presented an
adequate adjustment to the kinetic data with r2 0.97
for both volumetric and specific plasmid yield.
Plasmid specific and volumetric yields depend on
the biological system used, and on the culture condi-
tions. Cultures in lab-scale bioreactors using E. coli
DH5a and diverse fermentation approaches have been
reported recently [29]. High productivity of 4.00 and
6.75mg pDNA/(L h) was obtained in this study in
batch mode for glucose and glycerol, respectively. This
short-term culture permits the maintenance of cellular
plasmid content without a significant dilution, as seen
in Figure 2(c,d), but in the long run the use of this
approach will entail higher operational costs.
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Figure 2. Kinetics of batch fermentation. Biomass growth and substrate-consumption kinetics using glucose (a) and glycerol
(b). Experimental mean with standard deviation (±SD) of cell [] and substrate [] concentrations. Plasmid formation kinetics
using glucose (c) and glycerol (d). Experimental mean with SD of VY [], SY []. [—] Adjusted model.
Table 1. Operating and kinetic parameters of batch and EFP cultures.
Symbol Glucose Glycerol Units Description
Batch parameters
X0 1.00 1.00 OD600 Initial biomass concentration
Xm 16.36 12.50 OD600 Maximum biomass concentration
mm 0.55 0.50 1/h Maximum specific growth rate
YX/S 1.16 0.86 OD600 L/g Yield coefficient (biomass/glucose)
YP/X 1.28 2.78 mg/(L OD600) Yield coefficient (plasmid/biomass)
EFP parameters
X0 1.00 1.00 OD600 Initial biomass concentration
Xm 86.00 66.50 OD600 Maximum biomass concentration
Ks 0.10 0.10 g/L Saturation constant
mp 0.25 0.25 1/h Maximum specific growth rate
VD 3.00 3.00 L Total volume fed
YX/Sp 1.16 0.86 OD600/(g/L) Yield coefficient for the perfusion phase (biomass/glucose)
YP/Xb 1.44 2.85 mg/(L OD600) Yield coefficient for the batch phase (plasmid/biomass)
YP/Xp 1.90 3.65 mg/(L OD600) Yield coefficient for the perfusion phase
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Plasmid purity
The agarose gel electrophoresis images (Figure 3) of
the samples taken during the batch cultures for
glucose or glycerol showed predominantly CCC pDNA
with small amounts of OC pDNA. When using glucose
(Figure 3(a)), the plasmid content decreases as the
fermentation time progresses, as was determined in
the HIC-HPLC analysis and discussed above. However,
plasmid content (Figure 3(b)) increased with glycerol,
due to a lower specific growth rate.
Exponential-fed perfusion cultures
Cell growth and substrate consumption
Using the experimental parameters obtained in the
batch cultures, we reproduced the EFP cultures.
Figure 4(a, b) shows the corresponding biomass and
substrate kinetics. The continuous lines in the figure
represent the fitted EFP model.
The batch phase of the experiment using glucose
(Figure 4(a)) was run for 5.5 h, which enabled culture
at lmax and minimized the operating time to reach
the final biomass concentration of 86.0 OD600. This
period was followed by an exponential phase of 6.5 h,
initiated using a feeding strategy to accomplish a
constant lp¼ 0.25 h1, and to increase the plasmid
specific yield. Analogously, the batch and exponential
phases of the experiment using glycerol (Figure 4(b))
lasted 5.0 and 7.0 h respectively. A maximum cell
density of 66.5 OD600 was obtained at the end of
the experiment.
In both EFP experiments, the model presented an
adequate adjustment to the kinetic data, attaining
r2¼ 0.99. The final biomass concentration using
glucose was 31% higher than with glycerol.
Similar results have been reported previously [33]. The
corresponding operating and kinetic parameters are
shown in Table 1.
Plasmid kinetics and yield
The kinetics of plasmid production determined by
HIC-HPLC in the EFP cultures are shown in
Figure 4(c,d). The continuous line represents the fitted
plasmid model.
In the glucose EFP experiment (Figure 4(c)) the SY
was 1.86mg/(LOD600) and the VY was 160.00mg/L.
Plasmid SY decreases during the batch phase due to a
dilution effect. Once the EFP phase begins, the SY
starts to increase, since the plasmid dilution effect is
minimized. However, the volumetric yield increases
due to the quantitative effect of cell growth.
In the glycerol EFP experiment (Figure 4(d)), the
final plasmid SY was 3.5mg/(LOD600) and the VY was
233.0mg/L. Plasmid SY increases in the batch and
EFP phases due the lower specific growth rate
attained. In both EFP experiments the model pre-
sented an adequate adjustment to the kinetic data
with r2 0.95.
The plasmid productivities were 13.33 and
19.40mg/(L h) for glucose and glycerol respectively,
representing 1–3-fold increases with respect to
previously reported fed-batch cultures at bench and
pilot scale using E. coli DH5a [33–35]. The economic
feasibility of EFP cultures requires that the increment
in revenues expected from higher plasmid productivity
outpaces the additional expenses related to the
pumps and filters required for the system.
Plasmid purity
Agarose gel electrophoresis images of the samples
taken during the EFP cultures showed predominately
CCC pDNA with small amounts of OC pDNA (Figure 5).
Using glucose (Figure 5(a)), the plasmid content
Figure 3. Agarose gel electrophoresis of cell lysate of the batch fermentation. Glucose culture (a) lanes 1–5 correspond to time 0,
2, 4, 5, and 5.5 h respectively. Glycerol culture, (b) lanes 6–9 correspond to 0, 2, 4 and 5 h respectively. (M) Molecular
weight marker.
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decreased as the fermentation time progressed during
the batch phase, then increased during the EFP phase
(based on the HIC-HPLC analysis and discussed
above). The corresponding image for glycerol culture
(Figure 5(b)) showed a steady increase of plasmid
content.
Figure 4. Kinetics of the EFP fermentation. Exponential feed with lp¼ 0.25 h1. Biomass and substrate consumption kinetics
using glucose (a) and glycerol (b). Experimental cell concentration [] and substrate concentration []. Plasmid formation kinetics
using glucose (c) and glycerol (d). Experimental VY [] and SY []. [—] Fitted model.
Figure 5. Agarose gel electrophoresis of cell lysate of the EFP fermentation. Glucose culture (a) lanes 1–8 correspond to samples
at time 0, 4, 5, 5.5, 6, 8, 10, and 12 h respectively. Glycerol culture (b) lanes 9–16 correspond to time 0, 4, 5, 6, 8, 10, 11, and
12 h respectively. (M) Molecular weight marker.
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Oxygen control
The oxygen control charts for the batch and EFP
experiments are shown in Figure 6. In the course of
glucose cultures (Figure 6(a,b)), the DO comportment
was steadier than in cultures using glycerol
(Figure 6(c,d)). This behaviour was also steadier than
DO variations observed in cultures reported previ-
ously [36].
In E. coli aerobic cultures using glucose as sub-
strate, the biomass yield based in oxygen (YX/O2) is
bigger than the respective parameter using glycerol
[37,38]. This implies a lower oxygen uptake rate (OUR)
in glucose- than in glycerol-limited cultures and
leads to a synergetic effect, since less aeration and
consequently less antifoam is necessary in the culture.
Under these conditions, a better oxygen control and
transfer rate (OTR) is obtained, due to silicone oil-
containing antifoams reducing the OTR even at low
concentrations [39,40].
Conclusions
The substrate-source flexibility of an EFP system to
produce the plasmid pVAX1-NH36 for use as leishman-
iasis vaccine was investigated using batch and EFP
cultures; with glucose or glycerol as limiting substrate.
The kinetic parameters obtained in the batch cultures
were used to reproduce the EFP cultures. The model
of these cultures presented an adequate adjustment
to the kinetic data. A higher productivity of the EFP
cultures compared to conventional bioprocesses using
either substrate source was found. The EFP using
glycerol presented higher plasmid productivity but
resulted in higher operational cost than EFP glucose
cultures, in spite of the constant decrease in glycerol
prices. On the other hand, the oxygen demand and
control were better during the glucose fermentation.
These results may suggest the use of glycerol during
the batch phase culture to minimize the plasmid
dilution, and glucose during the EFP phase for a
Figure 6. Dissolved oxygen control. Batch (a) and EFP (b) experiments using glucose and batch (c) and EFP (d) experiments
using glycerol.
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better oxygen control, since in this phase the specific
growth rate is controlled, and plasmid dilution is mini-
mized. The novel aspect of this work is the demonstra-
tion of the flexibility of EFP cultures for production of
pDNA vaccines, which is advantageous for industrial
development of plasmid-based biopharmaceuticals.
Our data suggest that E. coli engineering to increase
pDNA production using glucose can be circumvented
with an EFP culture, reducing the host strain develop-
ment costs. In addition, the greater productivity of EFP
cultures entails a reduction in manufacturing costs.
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